Tupai (Beijing) Medical Technology Co., LTD. (hereinafter referred to as "Tupai Medical"), a leading company in the independent research and development of ophthalmic equipment in China, has recently completed a Series C financing of nearly RMB300 million.
This round of financing is led by Shanghai Shengshi Capital, followed by Daoyuan Capital, Kunlun Capital, Hao Yue Fund and other institutions, and the old shareholder Aibo Qingshi Capital continues to increase its size.
Since its establishment in October 2017, Tupai Medical has developed rapidly. It has completed 6 rounds of financing in 5 years, and continues to lead the rise of domestic ophthalmic equipment.
In this regard, the arterial network has been following up for a long time.
As the golden track of the capital market in recent years, the ophthalmic medical industry has attracted much attention.
Previously, listed enterprises such as Aier Ophthalmology, Purui Ophthalmology, He's Ophthalmology and Huaxia Ophthalmology emerged in the field of ophthalmology service, creating a good story in the industry;
In the field of ophthalmic medicine, Kanghong Pharmaceutical, Yisheng Biology, Xingqi ophthalmic medicine and other industry leaders;
In the field of ophthalmic high-value consumables, Opcom, Aibo Medical and other leading forces have broken out of the "siege of imported products" in recent years, and laid a solid foundation of market share in the industry.
Unfortunately, in the field of ophthalmic equipment, few enterprises based on independent research and development in the past years can not compete with imported brands in scale.